-
Saracatinib (AZD-0530) is an
experimental drug
being developed by AstraZeneca. It acts as a dual
kinase inhibitor, with
selective actions as a Src inhibitor...
- plates. Recently, as of 2021[update], a
potential therapeutic candidate,
saracatinib, is in
phase III
clinical trials as a
potent heterotopic ossification...
-
developed for the
treatment of
chronic myelogenous leukemia by Pfizer.
Saracatinib, the
first Src
inhibitor to show
inhibition of the Src
pathway in human...
-
sapropterin dihydrochloride (USAN)
sapropterin (INN)
saquinavir (INN)
saracatinib (USAN, INN)
Sarafem sarafloxacin (INN)
saralasin (INN)
sarcolysin (INN)...
-
synaptic density imaging with 11C-UCB-J
detects treatment effects of
saracatinib (AZD0530) in a
mouse model of Alzheimer's disease".
Journal of Nuclear...
- Saint-Paul L,
Lucchi G, Uzan B,
Ballerini P, et al. (September 2018). "
Saracatinib impairs maintenance of
human T-ALL by
targeting the LCK
tyrosine kinase...
- safety, tolerability, and
central nervous system availability of AZD0530 (
saracatinib) in Alzheimer's disease". Alzheimer's
Research & Therapy. 7 (1): 35....
- safety, tolerability, and
central nervous system availability of AZD0530 (
saracatinib) in Alzheimer's disease".
Alzheimers Res Ther. 7 (1): 35. doi:10.1186/s13195-015-0119-0...
